- Home
- AEVA vs STTK Comparison
AEVA vs STTK Comparison
Compare AEVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- STTK
- Stock Information
- Founded
- AEVA 2019
- STTK 2016
- Country
- AEVA United States
- STTK United States
- Employees
- AEVA N/A
- STTK N/A
- Industry
- AEVA Auto Parts:O.E.M.
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- STTK Health Care
- Exchange
- AEVA Nasdaq
- STTK Nasdaq
- Market Cap
- AEVA 177.0M
- STTK 173.6M
- IPO Year
- AEVA N/A
- STTK 2020
- Fundamental
- Price
- AEVA $2.41
- STTK $3.86
- Analyst Decision
- AEVA Buy
- STTK Strong Buy
- Analyst Count
- AEVA 5
- STTK 3
- Target Price
- AEVA $10.03
- STTK $10.67
- AVG Volume (30 Days)
- AEVA 261.6K
- STTK 150.7K
- Earning Date
- AEVA 08-07-2024
- STTK 11-07-2024
- Dividend Yield
- AEVA N/A
- STTK N/A
- EPS Growth
- AEVA N/A
- STTK N/A
- EPS
- AEVA N/A
- STTK N/A
- Revenue
- AEVA $6,540,000.00
- STTK $4,123,999.00
- Revenue This Year
- AEVA $109.97
- STTK $164.45
- Revenue Next Year
- AEVA $136.96
- STTK N/A
- P/E Ratio
- AEVA N/A
- STTK N/A
- Revenue Growth
- AEVA 89.40
- STTK 380.09
- 52 Week Low
- AEVA $2.20
- STTK $1.33
- 52 Week High
- AEVA $7.25
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- AEVA 35.69
- STTK 57.18
- Support Level
- AEVA $2.36
- STTK $3.37
- Resistance Level
- AEVA $2.60
- STTK $3.75
- Average True Range (ATR)
- AEVA 0.23
- STTK 0.24
- MACD
- AEVA -0.06
- STTK 0.08
- Stochastic Oscillator
- AEVA 4.55
- STTK 88.57
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.